IPSEN/ FR0010259150 /
2024-05-31 9:05:05 AM | Chg. +0.10 | Volume | Bid5:30:02 PM | Ask5:30:02 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
119.30EUR | +0.08% | 0 Turnover: - |
-Bid Size: - | -Ask Size: - | 10.11 bill.EUR | 1.00% | 15.48 |
GlobeNewswire
05-15
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
05-13
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticip...
GlobeNewswire
04-25
GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)
GlobeNewswire
04-24
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines...
GlobeNewswire
04-22
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological di...
GlobeNewswire
04-15
GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents
GlobeNewswire
04-05
GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report ...
GlobeNewswire
04-02
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid t...
GlobeNewswire
03-20
Mountain America Credit Union Partners with Operation Warm to Donate Shoes to Local Children